# Ascentage Pharma

Source: https://onco.cc/companies/ascentage-pharma/  
OnCo record `ascentage-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax.

## Summary

Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575) is a BCL-2 inhibitor in phase 3 trials in chronic lymphocytic leukaemia and other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ascentage Pharma Group Inc.; 亚盛医药
- Tags: ctgov-sponsor
- HQ: Suzhou
- Type: biotech
- Website: https://www.ascentage.com

## Sources

- Official website: https://www.ascentage.com
- ClinicalTrials.gov: trials led by Ascentage Pharma: https://clinicaltrials.gov/search?lead=Ascentage%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Ascentage_Pharma

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/targets/bcr-abl/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/ascentage-pharma.json